Adaptimmune Therapeutics PLC reports results for the quarter ended in December - Earnings Summary

Adaptimmune Therapeutics

06/03/2023 12:39

* Adaptimmune Therapeutics PLC  ADAP.OQ  reported a
quarterly
adjusted loss of 3 cents​​ per share for the quarter ended in
December. The mean expectation of eight analysts for the quarter
was for a loss of 25 cents per share.
    * Revenue rose 3.5% to $35.25 billion from a year ago;
analysts
expected $4.13 million. 
    * Verizon Communications Inc's reported EPS for the quarter
was
$1.56​.
    * The mean earnings estimate of analysts had fallen by
about 2.1%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Verizon Communications Inc shares had fallen by 2.9% this
quarter.
    * The company reported quarterly net income of $6.58
billion.
    * Wall Street's median 12-month price target for Verizon
Communications Inc is $44.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 21
"hold" and 3 "sell" or "strong sell." 

This summary was machine generated from Refinitiv data March 6
at 12:39 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      1.19           1.19           Met
 Sep. 30 2022      1.29           1.32           Beat
 Jun. 30 2022      1.32           1.31           Missed
 Mar. 31 2022      1.35           1.35           Met